|
Market Closed -
London S.E.
11:35:12 2026-10-16 am EDT
|
5-day change | 1st Jan Change | ||
| 1,862.50 GBX | -0.32% |
|
+6.43% | +2.08% |
| Oct. 16 | UK stocks set for weekly gains as investors seek shelter in defensive sectors | RE |
| Oct. 15 | Pennsylvania secures $4 billion in investments, governor says | RE |
| Market Cap | 74.63B 99.56B 88.5B 82.03B 141B 9,449B 143B 986B 387B 4,931B 374B 366B 15,719B | P/E 2026 * |
14.2x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 95.79B 128B 114B 105B 181B 12,128B 184B 1,265B 496B 6,329B 480B 469B 20,175B | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.73% | Yield 2027 * | 4.01% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -0.32% | ||
| 1 week | +6.43% | ||
| Current month | +1.66% | ||
| 1 month | -1.97% | ||
| 3 months | -2.82% | ||
| 6 months | -13.13% | ||
| Current year | +2.08% |
| 1 week | 1,740 |  | 2,158 |
| 1 month | 1,735.5 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 9/18/26 | Buy | Director | 768 | 0.0000% | ||
| 9/18/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | +6.43% | +14.62% | +23.82% | 99.56B | |
| +0.43% | +6.59% | +56.57% | +106.64% | 1,120B | |
| +0.90% | -2.25% | +32.26% | +63.73% | 616B | |
| +0.71% | +3.24% | +24.33% | +91.33% | 504B | |
| -0.13% | +5.98% | +33.66% | +50.18% | 367B | |
| +0.52% | +0.24% | +72.13% | +40.11% | 360B | |
| -0.95% | +4.70% | +19.65% | +42.71% | 288B | |
| -1.98% | +3.73% | -0.89% | +10.43% | 258B | |
| -0.35% | +4.25% | +44.74% | +52.06% | 234B | |
| -0.75% | +3.32% | +27.18% | +94.07% | 194B | |
| Average | -0.19% | +3.90% | +32.43% | +57.51% | 404.05B | |
| Weighted average by Cap. | +0.12% | +3.90% | +38.73% | +70.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.91B 45.24B 40.21B 37.27B 63.99B 4,294B 65.02B 448B 176B 2,241B 170B 166B 7,143B | 35.52B 47.39B 42.12B 39.04B 67.03B 4,497B 68.1B 469B 184B 2,347B 178B 174B 7,482B |
| Net income | 5.32B 7.1B 6.31B 5.85B 10.04B 674B 10.2B 70.31B 27.57B 352B 26.64B 26.08B 1,121B | 6.31B 8.42B 7.48B 6.93B 11.9B 799B 12.09B 83.34B 32.68B 417B 31.58B 30.91B 1,329B |
| Net Debt | 21.16B 28.22B 25.09B 23.25B 39.92B 2,679B 40.56B 280B 110B 1,398B 106B 104B 4,456B | 18.27B 24.37B 21.66B 20.08B 34.48B 2,313B 35.03B 241B 94.64B 1,207B 91.47B 89.52B 3,848B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | GBX 1,862.50 | -0.32% | 12,806,915 |
| 26-10-15 | GBX 1,868.50 | +2.89% | 12,523,823 |
| 26-10-14 | GBX 1,816.00 | +3.59% | 7,627,221 |
| 26-10-13 | GBX 1,753.00 | -1.02% | 6,613,488 |
| 26-10-12 | GBX 1,771.00 | +1.20% | 3,352,492 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
